Form 8-K · Current Report · Filed 2026-06-22
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal
AbbVie Inc. announced on June 22, 2026, a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion. The acquisition, expected to close in Q3 2026, is anticipated to be accretive to AbbVie's adjusted diluted earnings per share beginning in 2032. The deal includes Apogee's pipeline of clinical-stage candidates focused on inflammatory and immunological diseases, including atopic dermatitis and asthma.
- Filer
- AbbVie Inc. ABBV · NYSE
- Filed
- Accession
- 0001104659-26-076067
- CIK
- 0001551152
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$216.49
Next session
+8.4%
Since filing
+15.9%
Latest close
$250.94
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABBV reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ABBV insiders reported 13 Form 4 transactions — net buying of $49K.
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Never miss another ABBV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.